1 Pain Therapeutics Inc (PTIE) Stock Chart For Last 6 Months
3 Comparison Between Pain Therapeutics Inc (PTIE) And S&P 500 From May-2020 to Oct-2020
The first section will help you observe the performance of PTIE stock in the last 6 months. Now you will see a line graph representing the weekly average values. You may have to look for sharp changes and analyze the reasons if any. Such an analysis will help you look for factors that you may otherwise miss.
4 Highest Weekly Price of PTIE Stock In Last 6 Months
Several events both local and national may have impacted the stock prices over a period of 6 months. Some events impact the entire financial system and stock markets, some impact only certain industries while some impact only a single or handful of companies. The below section compares PTIE stock with S&P 500, a widely used benchmark index
5 Lowest Weekly Price of PTIE In Last 6 Months
The fourth section will help you learn the highest weekly prices of Pain Therapeutics Inc (PTIE) in the last six months.
Conclusion
The final section will help you learn the lowest weekly performances of Pain Therapeutics Inc (PTIE) stock.
Want to become a smart investor?
We hope the above report will help you do a basic analysis of Pain Therapeutics Inc (PTIE)'s price movement and performance (growth) over the last six months.
Component Grades
Netcials reports section helps you with deep insights into the performance of various assets over the years. We are constantly upgrading and updating our reports section. Feel free to access them. Do not forget to leave your feedback.
Pain Therapeutics, Inc. (PTIE) Company Bio
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
About Pain Therapeutics
Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs in the United States. The companys lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief.
Golden Star Signal
Pain Therapeutics, Inc., a biopharmaceutical company, develops novel drugs in the United States. The companys lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone for pain relief.
What is pain therapeutics?
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Is Pain Therapeutics a shaker?
Pain Therapeutics is a biopharmaceutical company, which engages in the development of novel drugs. Its drug candidate includes REMOXY, which is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use.
Who is the President of Pliant Therapeutics?
Pain Therapeutics, Inc. (NASDAQ: PTIE) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 60% upturn. Why such a bullish parade? A Phase 1 clinical trial of PTIE’s new investigational drug, PTI-125, showed that it was safe and well-tolerated in healthy volunteers, paving the way for a Phase 2 trial in adults with Alzheimer’s Disease.
What is the Vickers top buyer and seller report?
(Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M .D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a virtual fireside chat as part of the Piper Sandler Lung Day on Friday, October 15, 2021, at 11:00 a.m. ET. A replay of the Piper Sandler virtual fir
What is PLN-1474?
Daily – Vickers Top Buyers & Sellers for 06/09/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
What is a positive phase 2 clinical trial readout?
Pliant has also developed PLN-1474, a small-molecule selective inhibitor of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis , which Pliant has transferred to Novartis pursuant to our development partnership.
